Amylin's long-delayed diabetes drug gets FDA nod
Federal health regulators have approved Amylin Pharmaceutical's long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company's current offering, Byetta.
The Food and Drug Administration approval comes after two previous rejections in 2010, when the agency asked Amylin to conduct a new study of the drug's effects on the heart. The agency has heightened its scrutiny of diabetes treatments since GlaxoSmithKline's diabetes pill Avandia was linked to heart attacks.
Bydureon is a once-a-week version of Byetta, which is taken twice a day to help diabetes patients control their blood sugar. Amylin executives say the new drug's convenient regimen will give it a competitive advantage in the marketplace. However, last year Amylin reported disappointing results for Bydureon against Novo Nordisk's Victoza, a once-daily injection approved last January.
(Copyright 2012 by The Associated Press. All Rights Reserved.)
Your support matters.
You make MPR News possible. Individual donations are behind the clarity in coverage from our reporters across the state, stories that connect us, and conversations that provide perspectives. Help ensure MPR remains a resource that brings Minnesotans together.